Get the Daily Brief
Latest Biotech News
Scribe readies first CRISPR therapy: clinic start targeted for summer
Scribe Therapeutics, a company developing therapeutics based on novel CRISPR enzymes, said it plans to begin testing its first gene‑editing therapy in the clinic this summer. The program...
Illumina unveils Billion Cell Atlas... massive dataset to train drug‑discovery AI
Illumina launched the Billion Cell Atlas, an initial installment of a planned five‑billion‑cell genetic perturbation dataset built in partnership with AstraZeneca, Merck and Eli Lilly, intended to...
Boston Scientific to buy Penumbra — $14.5B deal and device nod
Boston Scientific announced an agreement to acquire Penumbra for about $14.5 billion, a transaction aimed at expanding Boston Scientific’s presence in thrombectomy and embolization markets....
NVIDIA deepens lab bets: $1B with Lilly, Thermo Fisher tie-up
NVIDIA and Eli Lilly unveiled a five-year, $1 billion collaboration to build an AI co‑innovation lab focused on drug discovery, committing compute and model development to accelerate in‑silico...
BloodPAC issues MRD validation protocols — companies ready to commercialize
The Blood Profiling Atlas in Cancer (BloodPAC) consortium published generic protocols for analytical validation of tumor‑informed circulating tumor DNA (ctDNA) assays for minimal residual disease...
Cellares signs lease for European Smart Factory at Leiden Bio Science Park
Cellares signed a long‑term lease for a Smart Factory at Leiden Bio Science Park that will serve as the company’s European headquarters and regional integrated development and manufacturing...
J&J’s Tecvayli posts positive Phase 3 readout in earlier myeloma
Johnson & Johnson reported positive Phase 3 survival outcomes for Tecvayli (teclistamab) in an earlier‑line multiple myeloma setting, supporting the drugmaker’s strategy to expand use beyond later...
Natera doubles down on Signatera: ASPs, tech upgrades and reimbursement bets
Natera told investors that Signatera drove record growth and will remain a revenue engine in 2026, with Q4 being the company’s fastest‑growing quarter for the MRD test. Management flagged expected...
Oral GLP‑1 race tightens: Lilly’s orforglipron review and label updates
Eli Lilly said the FDA is expected to decide on its oral obesity pill orforglipron in the second quarter of 2026 after granting Lilly a national priority review voucher intended to accelerate...
Illumina launches Billion Cell Atlas — pharma partners to power AI drug discovery
Illumina released the first installment of its Billion Cell Atlas, a genome‑wide genetic perturbation dataset designed to train AI models for drug discovery. Illumina named AstraZeneca, Merck and...
Liquid biopsy financing surges: Cyclomics raises €2.6M, Precede nets $84M
Dutch startup Cyclomics raised €2.6 million to move its Epinn methylation‑based cancer test and CyclomicsSeq assays toward CE‑IVD and eventual FDA clearance, aiming to commercialize its...
CRISPR clinic timeline: Scribe readies first in‑human study; Cas3 shows therapeutic promise
Scribe Therapeutics confirmed readiness to test its first CRISPR‑based therapeutic in humans this summer, moving the company’s novel CRISPR enzyme platform from preclinical development toward...
FDA removes suicide warning from GLP-1 labels – regulators update risk assessment
The FDA concluded a post-market evaluation and is moving to remove suicidal ideation and behavior warnings from labels for approved GLP‑1 obesity drugs. The agency’s review found no increased risk...
Illumina launches Billion Cell Atlas... AI drug discovery gets a training set
Illumina unveiled the Billion Cell Atlas, a genome‑wide genetic perturbation dataset intended to train foundation models for drug discovery and validate genetic targets at scale. Founding pharma...
Cellares signs lease in Leiden – European smart factory set for 2026
Cellares announced a long‑term lease for a new integrated development and manufacturing organization (IDMO) Smart Factory at Leiden Bio Science Park, establishing its European headquarters and...
Natera doubles down on Signatera: MRD upgrades and commercial cadence set for 2026
Natera executives said Signatera—its blood‑based minimal residual disease (MRD) assay—delivered record growth in Q4 2025 and will be enhanced with phased and structural variant tracking in a new...
PanMAN compresses pangenomes – a storage fix for large-scale genomics
Researchers from UC San Diego introduced PanMAN (Pangenome Mutation‑Annotated Network), a new file format and data structure that dramatically compresses large pangenome datasets while preserving...
Digital CRISPR diagnostics: Rapid C. auris detection and resistance profiling
A Wyss Institute team reported dSHERLOCK, a digital CRISPR‑based diagnostic that quantifies Candida auris and detects resistance mutations from swab samples with high sensitivity and speed. The...
J&J posts positive Phase 3 for Tecvayli – survival gains in earlier myeloma
Johnson & Johnson reported positive Phase 3 results for Tecvayli in an earlier‑line multiple myeloma setting, with survival outcomes supporting plans to expand use beyond later‑line indications....
Myriad maps MRD expansion at JPM – five cancer assays, early access plans
Myriad Genetics detailed a menu refresh at JP Morgan, committing to launch tissue‑informed minimal residual disease (MRD) tests across breast, renal, colorectal, endometrial, and ovarian cancers...